Mitchall Clark

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA.

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.

DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA.

Part of NantWorks LLC, NantPharma LLC is a company that manufactures injectable pharmaceutical products. The company is based in Lincolnshire, IL.